Hypercapnia is a central component of diverse respiratory disorders, while 'permissive hypercapnia' is frequently used in ventilatory strategies for patients with severe respiratory failure. This review will present data from recent studies relating to hypercapnia, focusing on issues that are of importance to anesthesiologists caring for the surgical and/or critically ill patient.
INTRODUCTION
Permissive hypercapnia (PHC) results from lung protective mechanical ventilation approaches, whereby elevated arterial CO 2 is accepted to minimize ventilator-induced lung injury (VILI). These approaches have been demonstrated to improve the outcome from acute respiratory distress syndrome (ARDS) [1, 2] . Ventilation strategies incorporating PHC are also well described in other diseases leading to acute respiratory failure in adults and children, including severe asthma and chronic obstructive pulmonary disease (COPD). Paralleling these developments is a growing body of knowledge regarding the mechanisms of action -both beneficial and deleterious -of hypercapnia and its associated acidosis, and extensive clinical experience attesting to the benign clinical profile of moderate hypercapnia, can be used to help guide the rational use of PHC at the bedside in the patient with severe respiratory failure.
This study reviews the physiology of hypercapnia, discusses the insights gained to date from basic scientific studies of hypercapnia and acidosis and considers the potential clinical implications of these findings for the management of patients with acute lung injury. The experimental and clinical studies of special interest, published within the annual period of review, have been highlighted.
&&
,12]. The effects of hypercapnia on the diaphragm are complex. Older studies suggest that hypercapnic acidosis (HCA) impairs diaphragmatic contractility and worsens diaphragmatic fatigue in spontaneously breathing individuals [15] . In recent studies, in which minute ventilation is controlled, HCA preserved diaphragmatic contractility and prevented prolonged ventilation-induced diaphragmatic dysfunction [16 && ] by reducing diaphragmatic myosin loss and inflammation [17 && ]. The clinical impact of hypercapnia on diaphragmatic function, especially with regard to weaning from mechanical ventilation, has yet to be elucidated.
Systemic hemodynamics and tissue oxygenation
HCA enhances tissue perfusion and oxygenation, through multiple mechanisms. HCA increases cardiac output (CO), improves lung mechanics and ventilation-perfusion matching, increases peripheral perfusion and enhances peripheral tissue hemoglobin oxygen unloading (Bohr effect). Hypercapnia increases CO through increased sympathoadrenal activity despite directly decreasing myocardial contractility [18] . Indeed, CO 2 increases cardiac index by 10-15% by each 10 mmHg of PaCO 2 increase [19, 20] , subcutaneous and muscle tissue oxygen tension in both animals and humans [19] [20] [21] [22] [23] [24] . In contrast, even a short period of hypocapnic alkalosis significantly reduces CO [20, 25] , portal blood flow, gut perfusion and splanchnic oxygen delivery [25] . Hypoventilation-induced HCA preserves hemodynamics in uncompensated experimental hemorrhagic shock [26] .
Much attention has focused recently on the potential for hypercapnia-mediated enhanced tissue perfusion to reduce postoperative wound infection. Fleischmann et al. [22] have shown in a small study that intraoperative hypercapnia was associated with significantly higher colon tissue oxygenation. Similar observations have been reported in morbidly obese surgical patients [23] . However, a recent multicenter randomized controlled trial (RCT), including 1206 patients undergoing colon surgery, failed to demonstrate clear benefits of intraoperative hypercapnia in surgical site infection (SSI) compared with normocapnia [27 && ].
Cerebrovascular regulation
Carbon dioxide is a key regulator of cerebrovascular tone. For each 1 mmHg change in PaCO 2 , there is a 1 to 2 ml/100 g/min change in global cerebral blood
KEY POINTS
Protective ventilatory strategies, which reduce lung stretch, require tolerance of 'permissive' hypercapnia and have improved outcome from ARDS. Evidence also supports the use of permissive hypercapnia strategies in acute severe asthma and chronic obstructive airways disease.
The physiologic effects of hypercapnia are increasingly well understood, while important recent insights have emerged regarding the cellular and molecular mechanisms of action of hypercapnia and acidosis.
The protective effects of acute hypercapnic acidosis in diverse preclinical models are mediated through potent effects on the host immune system, with key effects mediated through inhibition of the NF-kB pathway. Hypercapnia-mediated NF-kB inhibition may also explain several deleterious effects, including delayed epithelial wound healing and decreased bacterial killing.
A clear understanding of the effects and mechanisms of action of hypercapnia is central to determining its safety and therapeutic utility. When using permissive hypercapnia the clinician must decide for each specific patient what the appropriate trade-off is between the benefits of avoiding higher tidal volumes and the cost -and benefits -of the associated hypercapnia.
The potential for extracorporeal CO 2 removal technologies to facilitate even greater reductions in tidal and minute ventilation is clear, but awaits definitive studies.
flow [28] . Indeed, decreases in the reactivity of the cerebral vasculature to CO 2 may be a useful predictor of stroke risk [29 && ]. These effects are mediated by extracellular pH rather than by direct changes in PaCO 2 [30] . Mechanisms leading to cerebral vasodilatation or relaxation differ between adults and neonates. In adults, hypercapnia-induced vasodilatation is mediated, in part, by nitric oxide, whereas in neonates, the main mediators are prostaglandins [28] . These mediators then activate K-ATP and K-Ca channels through intracellular second messengers (cGMP/cAMP) resulting in decreased intracellularCa 2þ and vasodilation [31] . HCA-mediated increases in cerebral blood flow are a clear concern in the setting of reduced intracranial compliance. Indeed, traditional management of traumatic brain injury frequently included sustained hypocapnia to reduce cerebral blood volume and control raised intracranial pressure [32] . However, accumulating evidence has challenged this concept [33] . Sustained hypocapnia reduces cerebral O 2 supply [34] and increases brain ischemia [35] , increases vasospasm risk [36, 37] and worsens neuronal excitability [38] , thereby potentiating seizures [39] . More recent studies have shown that prehospital severe hypocapnia in traumatic brain injury patients worsens the outcome [40] [41] [42] .
HYPERCAPNIA IN PRECLINICAL DISEASE MODELS
Key insights into the effects of hypercapnia and acidosis -potentially beneficial and harmful -have emerged from preclinical models, in which it is possible to independently alter CO 2 tension and ventilation.
Ventilation-induced lung injury and repair
Substantial evidence demonstrates that moderate hypercapnia directly reduces VILI ( . Studies using clinically more relevant (V t ) have further underlined the potential for hypercapnia to protect against mechanical stretch [46] [47] [48] [49] . The biologic response to cyclic stretch occurs through mechanosensors that transmit signals from the deformed extracellular matrix to the interior of the cell [49, 50] . A recent study has demonstrated that HCA prevents the stretch-induced activation of p44/42 MAP-kinase [51 && ,59,60] (Fig. 1) . Furthermore, hypercapnia markedly reduced apoptosis, oxidative stress and inflammation by inhibiting the downward activation of the signal-regulating kinase 1 JNK/p38 MAP-kinase pathway in alveolar epithelial cells [50] . HCA also reduces stretch-induced lung inflammation and improves lung mechanics by inhibiting IkB-a degradation and nuclear p65 translocation [49] (Fig. 1) . The question whether the protective effect of HCA is mediated through CO 2 directly or pH in the context of VILI is still unknown. A recent study comparing the effect of HCA with normocapnic metabolic acidosis found that metabolic acidosis exerted similar protection against VILI as HCA [48] .
Of potential concern, hypercapnia may retard lung epithelial and cellular repair following stretchinduced injury. Doerr et al. [52] demonstrated first that HCA impairs plasma membrane resealing in VILI. HCA also delays epithelial wound closure in multiple pulmonary cell lines by reducing NF-kBdependent epithelial cell migration [53] .
Lung ischemia-reperfusion injury
Lung ischemia-reperfusion is a key mechanism of injury in diverse clinical situations, including lung transplantation, pulmonary embolism and ARDS. HCA has been demonstrated to attenuate ischemia-reperfusion-induced lung injury [54] by preserving endothelial capillary barrier function and reducing lipid peroxidation, peroxynitrite production and apoptosis in lung tissue [55, 58, 61] ( Table 1 ). The dose-response characteristic of hypercapnia and its efficacy in pulmonary as well as systemic ischemia-reperfusion-induced lung injury is well described [55, 58, 61] . Recent insights into the protective mechanisms of HCA include the demonstration that hypercapnia suppressed T-cell function in post-lung transplantation [56 && ]. Hypercapnia also attenuated ischemia-reperfusion-induced NF-kB pathway activation and reduced lung inflammation and apoptosis [62] , through mechanisms involving NF-kB inhibition and upregulation of the potent antioxidant enzyme, hemeoxygenase-1 [57 && ].
Sepsis
The potential for HCA to impair the host immune response in the setting of sepsis has raised serious concerns ( . Accumulating data suggest that hypercapnia may result in net benefit or harm depending on the site and duration of bacterial infection, the use of antibiotic therapy and whether the acidosis induced by hypercapnia is buffered or not. In pneumonia models, HCA is protective in early [64] and more established infections [65] . In contrast, hypercapnia may be harmful in prolonged, untreated pneumonia, likely by reducing neutrophil-mediated and macrophagemediated bacterial killing. This effect is completely In vitro Scratch wound 10,15% CO 2 rather than pH reduced the rate of wound closure (cell migration) in a dose-dependent manner via NF-kB pathway inhibition.
Shibata et al., 1998 [54]
In vivo (rat) Free radical 25% HCA attenuated free radical-induced injury via inhibition of endogenous xanthine oxidase and improved lung permeability. ]. Importantly, hypercapnia increased bacterial load in lung, spleen and liver, indicating significant level of systemic dissemination of bacterial sepsis [68 && ]. Physiologic buffering has also been shown to be deleterious in Escherichia coli-induced pneumonia [67] .
In systemic sepsis, HCA has a more favorable profile, protecting against early [70, 71] and more established [69] cecal ligation and puncture (CLP)-induced septic shock. In prolonged CLP sepsis, the protective effect of hypercapnia on lung injury was less marked [71] . Importantly, HCA did not alter BAL and peritoneal bacterial load in these studies. The potential for localized hypercapnia to exert protective effects in the setting of experimental abdominal sepsis has been demonstrated [72] [73] [74] 
Pulmonary hypertension
Pulmonary hypertension is a common complication of many clinical syndromes including ARDS, COPD and sepsis [77] . Although hypercapnia and acidosis should be clearly avoided in the context of severe established pulmonary hypertension, experimental data suggest that hypercapnia may attenuate pulmonary hypertension-induced vascular remodeling and impaired right ventricular function [78] [79] [80] [81] [82] . Peng et al. [80] recently demonstrated that hypercapnia reverses both structural and functional changes of hypoxia-induced pulmonary hypertension in juvenile rats by inhibition of RhoA/ Rho-kinase pathways and augmentation of lung tissue endothelial nitric oxide synthase and nitric oxide levels. Hypercapnia significantly decreased pulmonary vascular resistance and improved right ventricular performance following bleomycininduced lung injury, and reduced lung macrophage recruitment and TNF-a expression [81] . The effect of HCA on hypoxemic pulmonary vasoconstriction (HPV) remains unclear. A recent study has shown that CO 2 -independently from acidosis -increased hypoxemic pulmonary vasoconstriction during sustained hypoxemia and increased indices of lung edema possibly through increased inducible nitric oxide synthase activity [82] .
Alveolar fluid dynamics
The accumulation of pulmonary edema is the hallmark of ARDS, whereas subsequent clearance of alveolar fluid is central to ARDS resolution [83] . HCA reduces alveolar edema formation by inhibiting the increase in pulmonary capillary permeability included by free radicals [54] , ischemia-reperfusion [61] and high stretch ventilation [45] . In contrast, hypercapnia decreases alveolar fluid clearance, a process dependent on intact Na þ transport across the apical surface of alveolar epithelial cells. Hypercapnia -independent of pH -reduces alveolar fluid removal through intracellular activation of the protein kinase C z isotype, followed by phosphorylation and endocytosis of the Na þ /K þ -ATPase pump [84] . Hypercapnia also activates ERK1/2, a key regulatory molecule in Na þ /K þ -ATPase endocytosis [85] . Lecuona et al. [86 && ] showed that hypercapnia increases cAMP levels, activates PKA-Ia that leads to the activation of a-adductin -a cytoskeletal protein -mediated endocytosis of the Na þ /K þ -ATPase complex (Fig. 1) . Others have shown that increasing levels of CO 2 -not acidosis -rapidly activate c-jun N terminal kinase (JNK) resulting in decreased Na þ /K þ -ATPase pump activity [84, 87] .
Hypercapnia and NF-kB pathway
Several beneficial and the deleterious effects of HCA are mediated by the inhibition of the NF-kB pathway, a pivotal transcriptional activator in inflammation, injury and repair (Table 3) [49] demonstrated that HCA protected against VILI by inhibiting NF-kB activation. Importantly, HCA also reduces pulmonary epithelial wound repair by NF-kB pathway inhibition [53] . Cummins et al. [90] proposed the existence of an intracellular CO 2 molecular sensor linked to NF-kB pathway as a connection to innate immunity and inflammation. Others have shown that elevated CO 2 suppressed host defence by inhibiting NF-kB-dependent antimicrobial peptide gene expression in Drosophila resulting in increased mortality to bacterial infection [89] . High levels of CO 2 have also been shown to inhibit IL-6, TNF-a induction and phagocytosis in endotoxin-stimulated macrophages [91] . In the two latter studies, hypercapnia inhibited the NF-kB pathway without affecting IkB-a degradation, suggesting that other pathways or regulatory steps may have been involved in mediating the immunosuppressive effect of hypercapnia.
HYPERCAPNIA IN THE CLINICAL CONTEXT
Hypercapnia is frequently encountered in the setting of acute respiratory failure, both as a consequence of the disease process and as a result of strategies to minimize the potential of mechanical ventilation to stretch and further injure the lung.
Acute respiratory distress syndrome
To date, there have been no clinical trials examining the direct effect of hypercapnia on patients with ARDS. The potential of PHC to improve ARDS patients' survival as part of a protective ventilation strategy was suggested first by Hickling et al. [92, 93] . Subsequently, two RCTs comparing 'traditional' versus low V t showed improved survival in patients with ARDS [1, 2] . The secondary analysis of the ARMA trial suggested that patients with moderate HCA on study day 1 had significantly less odds ratio of death at 28 days in the setting of higher -but not lower -V t [94] . Because the primary aim of these trials was to investigate the effect of low stretch ventilation on ARDS, the direct relationship between PHC and lung protection remains to be determined. In a recent pilot study, a combination of stepwise recruitment-derecruitment with PHC was compared with lung protective ventilation [95] . This 'open lung' strategy resulted in significantly better lung compliance, systemic oxygenation in a 7-day period. However, arterial CO 2 and pH were not different between the two groups, suggesting that the achieved benefits were more likely related to better recruitment maneuver in the open-lung strategy group than to PHC per se.
Asthma
The utility of PHC in status asthmaticus was reported first by Darioli in 1984 [96] . Subsequent studies also confirmed that lowering minute ventilation, in conjunction with longer expiratory time, significantly reduces dynamic hyperinflation [97, 98] . In these studies, arterial CO 2 was kept intentionally at moderately elevated levels (63, 68 mmHg), whereas extremely high arterial CO 2 levels (150-200 mmHg) were also well tolerated in case series involving more severe presentations of asthma [99] . In spite of lack of RCTs to guide mechanical ventilation in status asthmaticus, PHC has been frequently used in patients with severe asthma admitted to ICUs both in Europe [100] and in North America [101] .
Chronic obstructive pulmonary disease
Respiratory failure during COPD exacerbations is a direct result of an acute increase in airway narrowing, with increased respiratory workload, similarly to acute severe asthma. Although noninvasive ventilation is the first-line ventilation strategy in patients with COPD exacerbations [102] , extreme respiratory muscle fatigue, CO 2 retention-induced 'coma' may necessitate invasive ventilation. The primary aim of mechanical ventilation in this setting is to reduce over-inflation and prevent VILI by reducing minute ventilation, decreasing inspiratory-expiratory ratio and increasing inspiratory flow rate. PHC is a useful approach to achieving these goals [103] .
Neonatal respiratory failure
Advances in perinatal medical care and ventilatory support have reduced mortality in high-risk newborns [104] . Prolonged mechanical ventilation, however, remains an important cause of pulmonary complications, such as bronchopulmonary dysplasia. Early observational studies suggested that PHC may lower the risk for bronchopulmonary dysplasia in premature infants. Mariani et al. [105] first reported that ventilation strategies allowing higher PaCO 2 levels (45-55 versus 35-45 mmHg) in preterm infants, in the first 96 h of life, result in faster weaning from mechanical ventilation. Subsequently, a larger multicenter RCT compared PHC with conventional ventilation with dexamethasone or placebo using a 2 Â 2 factorial design [106] . Although the trial was stopped due to adverse events in the dexamethasone groups, PHC decreased need for assisted ventilation at 36-week gestational age from 16% to just 1%. The potential of PHC to cause intracranial hemorrhage and adverse neurological outcomes in premature infants is a significant concern. Although an early meta-analysis of PHC in newborn infants demonstrated some trends toward decreased incidence of intracranial hemorrhage in the PHC group [107] , in a recent study higher ranges of hypercapnia (PaCO 2 : 55-65 mmHg) were associated with a significant increase in combined mental impairment and death in extremely preterm infants [108] . These data indicate that more research is needed to determine the optimal range of hypercapnia to balance the benefits and potential harms of PHC in preterm infants.
EXTRA-CORPOREAL CO 2 REMOVAL: THE FUTURE?
In recent years, new-generation extracorporeal CO 2 removal (ECCO 2 -R) devices have been developed that offer lower resistance to blood flow, have small priming volumes and have much more effective gas exchange [109] . These devices may further facilitate lung protective ventilation by allowing greater reductions in V t and plateau pressures in patients with severe ARDS, while avoiding the potential for severe hypercapnia -beyond levels that are generally well tolerated by patients under current PHC approaches. The rationale for ECCO 2 -R derives from studies demonstrating that lung hyperinflation still occurs in approximately 30% of ARDS patients despite lung protective ventilation strategies and the potential to further decrease mortality by reducing plateau pressures [110] . In a recent proof-ofconcept study, Terragni et al. [111] demonstrated that ECCO 2 -R could improve pulmonary protection and decrease pulmonary cytokine concentrations by allowing very low V t ventilation (3.5-5 ml/kg of PBW) in patients with ARDS. Most recently, Bein et al. [112 && ] demonstrated the feasibility of combining ECCO2-R with a tidal volume strategy of 3 ml/kg in 79 patients with established ARDS.
CONCLUSION
Protective ventilatory strategies involving PHC are widely used in patients with severe respiratory failure, particularly in ARDS, status asthmaticus, COPD and neonatal respiratory failure. The physiologic effects of hypercapnia are increasingly well understood, whereas important recent insights have emerged regarding the cellular and molecular mechanisms of action of hypercapnia and acidosis. Acute HCA is protective in multiple models of nonseptic lung injury. These effects are mediated by potent effects on the host immune system, with key effects mediated by inhibition of the NF-kB pathway. Hypercapnia-mediated NF-kB inhibition may also explain several deleterious effects, including delayed epithelial wound healing and decreased bacterial killing, which has been demonstrated to cause worse lung injury in prolonged untreated pneumonia models. The potential for extracorporeal CO 2 removal technologies to facilitate even greater reductions in tidal and minute ventilation is clear, but awaits definitive studies.
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